143 related articles for article (PubMed ID: 38278450)
21. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
[TBL] [Abstract][Full Text] [Related]
22. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
[TBL] [Abstract][Full Text] [Related]
23. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
[TBL] [Abstract][Full Text] [Related]
24. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
26. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
27. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
[TBL] [Abstract][Full Text] [Related]
29. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
[TBL] [Abstract][Full Text] [Related]
30. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
[TBL] [Abstract][Full Text] [Related]
31. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Skov BG
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
[TBL] [Abstract][Full Text] [Related]
32. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
[TBL] [Abstract][Full Text] [Related]
33. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
34. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
de Ruiter EJ; Mulder FJ; Koomen BM; Speel EJ; van den Hout MFCM; de Roest RH; Bloemena E; Devriese LA; Willems SM
Mod Pathol; 2021 Jun; 34(6):1125-1132. PubMed ID: 32759978
[TBL] [Abstract][Full Text] [Related]
35. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
[TBL] [Abstract][Full Text] [Related]
36. Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
Lee SE; Park HY; Lim SD; Han HS; Yoo YB; Kim WS
J Breast Cancer; 2020 Jun; 23(3):303-313. PubMed ID: 32595992
[TBL] [Abstract][Full Text] [Related]
37. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
38. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
39. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
Basu A; Chiriboga L; Narula N; Zhou F; Moreira AL
J Histotechnol; 2020 Dec; 43(4):174-181. PubMed ID: 33245263
[TBL] [Abstract][Full Text] [Related]
40. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
